Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial

on behalf of the, VX14-809-109 investigator group, VX14-809-109 investigator group

Research output: Contribution to journalArticle

106 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences